CASI Pharmaceuticals Files 6-K, Incorporates by Reference
Ticker: CASIF · Form: 6-K · Filed: Jul 22, 2025 · CIK: 1962738
Sentiment: neutral
Topics: sec-filing, 6-k, registration-statement
Related Tickers: CASI
TL;DR
CASI Pharma filed a 6-K, linking it to their F-3 registration. Standard update.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on July 22, 2025, for the month of July 2025. This report is incorporated by reference into the Company's Registration Statements on Form F-3, specifically File No. 333-283998. The company's principal executive office is located in Beijing, People's Republic of China.
Why It Matters
This filing indicates ongoing regulatory compliance and updates to the company's registration statements, which are crucial for its ability to issue securities.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not appear to contain significant new financial or operational information.
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Filer
- 333-283998 (dollar_amount) — Form F-3 File Number
- July 2025 (date) — Reporting Period
- 20250722 (date) — Filing Date
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer filed for the month of July 2025, and it incorporates information by reference into the Company's Registration Statements on Form F-3.
What are the specific Form F-3 file numbers mentioned in the filing?
The filing mentions incorporation by reference into the Company's Registration Statements on Form F-3, specifically File No. 333-283998.
Where is CASI Pharmaceuticals, Inc.'s principal executive office located?
The principal executive office of CASI Pharmaceuticals, Inc. is located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is July 22, 2025.
Does CASI Pharmaceuticals file annual reports under Form 20-F or Form 40-F?
The filing indicates that the registrant files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 22, 2025 regarding CASI Pharmaceuticals, Inc. (CASIF).